BACKGROUND: Increased natural killer (NK) activation has been associated with resistance to HIV-1 infection in several cohorts of HIV-1 exposed, uninfected individuals. Inheritance of protective NK receptor alleles (KIR3DS1 and KIR3DL1) has also been observed in a subset of HIV-1 exposed, uninfected individuals. However, the exact mechanism contributing to NK activation in HIV-1 exposed, uninfected intravenous drug users (EU-IDU) remains to be elucidated. OBJECTIVE: We investigated the role of both host genotype and pathogen-induced dendritic cell modulation of NK activation during high-risk activity in a cohort of 15 EU-IDU individuals and 15 control, uninfected donors from Philadelphia. DESIGN: We assessed the activation status of NK cells and dendritic cells by flow cytometry and utilized functional assays of NK-DC cross-talk to characterize the innate immune compartment in EU-IDU individuals. RESULTS: As previously reported, NK cell activation (CD69) and/or degranulation (CD107a) was significantly increased in EU-IDU individuals compared with control uninfected donors (P = 0.0056, n = 13). Genotypic analysis indicated that the frequency of protective KIR (KIR3DS1) and HLA-Bw4*80I ligands was not enriched in our cohort of EU-IDU individuals. Rather, plasmacytoid dendritic cells (PDC) from EU-IDU exhibited heightened maturation (CD83) compared with control uninfected donors (P = 0.0011, n = 12). When stimulated in vitro, both PDCs and NK cells from EU-IDU individuals maintained strong effector cell function and did not exhibit signs of exhaustion. CONCLUSION: Increased maturation of PDCs is associated with heightened NK activation in EU-IDU individuals suggesting that both members of the innate compartment may contribute to resistance from HIV-1 infection in EU-IDU.
BACKGROUND: Increased natural killer (NK) activation has been associated with resistance to HIV-1 infection in several cohorts of HIV-1 exposed, uninfected individuals. Inheritance of protective NK receptor alleles (KIR3DS1 and KIR3DL1) has also been observed in a subset of HIV-1 exposed, uninfected individuals. However, the exact mechanism contributing to NK activation in HIV-1 exposed, uninfected intravenous drug users (EU-IDU) remains to be elucidated. OBJECTIVE: We investigated the role of both host genotype and pathogen-induced dendritic cell modulation of NK activation during high-risk activity in a cohort of 15 EU-IDU individuals and 15 control, uninfected donors from Philadelphia. DESIGN: We assessed the activation status of NK cells and dendritic cells by flow cytometry and utilized functional assays of NK-DC cross-talk to characterize the innate immune compartment in EU-IDU individuals. RESULTS: As previously reported, NK cell activation (CD69) and/or degranulation (CD107a) was significantly increased in EU-IDU individuals compared with control uninfected donors (P = 0.0056, n = 13). Genotypic analysis indicated that the frequency of protective KIR (KIR3DS1) and HLA-Bw4*80I ligands was not enriched in our cohort of EU-IDU individuals. Rather, plasmacytoid dendritic cells (PDC) from EU-IDU exhibited heightened maturation (CD83) compared with control uninfected donors (P = 0.0011, n = 12). When stimulated in vitro, both PDCs and NK cells from EU-IDU individuals maintained strong effector cell function and did not exhibit signs of exhaustion. CONCLUSION: Increased maturation of PDCs is associated with heightened NK activation in EU-IDU individuals suggesting that both members of the innate compartment may contribute to resistance from HIV-1 infection in EU-IDU.
Authors: Maureen P Martin; Ying Qi; Xiaojiang Gao; Eriko Yamada; Jeffrey N Martin; Florencia Pereyra; Sara Colombo; Elizabeth E Brown; W Lesley Shupert; John Phair; James J Goedert; Susan Buchbinder; Gregory D Kirk; Amalio Telenti; Mark Connors; Stephen J O'Brien; Bruce D Walker; Peter Parham; Steven G Deeks; Daniel W McVicar; Mary Carrington Journal: Nat Genet Date: 2007-05-13 Impact factor: 38.330
Authors: Wassim M Ballan; Bien-Aimee N Vu; Brian R Long; Christopher P Loo; Jakob Michaëlsson; Jason D Barbour; Lewis L Lanier; Andrew A Wiznia; Jacobo Abadi; Glenn J Fennelly; Michael G Rosenberg; Douglas F Nixon Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Michael R Weed; Lucy M Carruth; Robert J Adams; Nancy A Ator; Robert D Hienz Journal: J Neuroimmune Pharmacol Date: 2006-07-14 Impact factor: 4.147
Authors: Marcus Altfeld; Elizabeth T Kalife; Ying Qi; Hendrik Streeck; Mathias Lichterfeld; Mary N Johnston; Nicole Burgett; Martha E Swartz; Amy Yang; Galit Alter; Xu G Yu; Angela Meier; Juergen K Rockstroh; Todd M Allen; Heiko Jessen; Eric S Rosenberg; Mary Carrington; Bruce D Walker Journal: PLoS Med Date: 2006-10 Impact factor: 11.069
Authors: Krystal Colón; David W Speicher; Peter Smith; Mack Taylor; David S Metzger; Luis J Montaner; Costin Tomescu Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Costin Tomescu; Kelly E Seaton; Peter Smith; Mack Taylor; Georgia D Tomaras; David S Metzger; Luis J Montaner Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Adam J Ritchie; Suzanne L Campion; Jakub Kopycinski; Zoe Moodie; Z Maggie Wang; Kruti Pandya; Stephen Moore; Michael K P Liu; Simon Brackenridge; Kristin Kuldanek; Kenneth Legg; Myron S Cohen; Eric L Delwart; Barton F Haynes; Sarah Fidler; Andrew J McMichael; Nilu Goonetilleke Journal: J Virol Date: 2011-01-26 Impact factor: 5.103